(redirected from Inosine monophosphate)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.


C10H12N4O5 A compound occurring in muscle; a hydrolysis product of inosinic acid.



(hypoxanthine riboside), a nucleoside consisting of the nitride purine base hypoxanthine and the carbohydrate ribose. Inosine is the intermediate product of nucleic acid metabolism. It is formed in the organism during the deamination of adenosine and also by synthesis from a free base according to the reaction hypoxanthine + ribose- 1 -phosphate ⇆ inosine + phosphate. This reversible reaction is catalyzed by the enzyme nucleoside phosphorylase.

References in periodicals archive ?
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
AVN944 is an orally bioavailable inhibitor of inosine monophosphate dehydrogenase 1 and 2 (IMPDH).
This suggests that MPNs were preferentially methylated by thiopurine methyltransferase between 6 and 20 h, rather than converted by inosine monophosphate dehydrogenase and guanosine monophosphate synthetase into TGNs.
Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model.
4] Nonstandard abbreviations: PK, pharmacokinetics; PD, pharmacodynamics; CsA, cyclosporine; AUC, area under the (drug concentration-time) curve; MMF, mycophenolate mofetil; MPA, mycophenolic acid; IMPDH, inosine monophosphate dehydrogenase; MPAG, mycophenolic acid glucuronide.
MPA mediates its effect by inhibiting inosine monophosphate dehydrogenase (1MPDH), an enzyme involved in the de novo biosynthesis of purine nucleotides [14,15].
Effect of human T lymphocyte activation on inosine monophosphate dehydrogenase expression.
VX-148 is a second- generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH).
Based on clinical results and an analysis of patient need, Vertex is focusing its resources on developing VX-497, an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMPDH), for the treatment of HCV.
VX-497 is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) being developed by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX).